Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | UNG | P13051 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | LDHB | P07195 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13083100 | 0.85 | ALDH1A1 (0.47) | CYP3A4MAPTSRCALDH1A1MAPK1 | |
| SCHEMBL9440089 | 0.84 | TTR (0.49) | CYP3A4MAPTACHEALDH1A1MAPK1 | |
| SCHEMBL9440090 | 0.84 | TTR (0.49) | CYP3A4MAPTACHEALDH1A1MAPK1 | |
| SCHEMBL29017440 | 0.82 | SRC (0.46) | CYP3A4MAPTSRCALDH1A1MEN1 | |
| SCHEMBL3612970 | 0.80 | POLB (0.46) | CYP3A4MAPTSRCALDH1A1MAPK1 | |
| SCHEMBL7807471 | 0.77 | CA12 (0.53) | CYP3A4MAPTALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL4283013 | 0.77 | CYP3A4 (0.52) | CYP3A4MAPTACHESRCALDH1A1 | |
| Formamide SCHEMBL28038646 | 0.76 | KDM4E (0.48) | CYP3A4MAPTACHEALDH1A1MAPK1 | |
| Acetaldehyde SCHEMBL10782292 | 0.76 | CYP3A4 (0.67) | CYP3A4MAPTACHEALDH1A1MAPK1 | |
| SCHEMBL377596 | 0.75 | KDM4E (0.55) | CYP3A4MAPTACHEALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951708-B1 | PIPERAZINE DERIVATIVE USEFUL AS A CCR5 ANTAGONIST | MERCK SHARP & DOHME (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| EP-1632479-B1 | Pharmaceutical compositions comprising CCR5 antagonizing piperazine derivatives | SCHERING CORP (US) | 2011-01-12 | — | — | EP | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-08-07 | — | — | US | disclosed |
| WO-2007050375-A2 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20060105964-A1 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| EP-1632479-A2 | Piperazine derivatives useful as ccr5 antagonists | SCHERING CORPORATION (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1175401-B1 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORP (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20040067961-A1 | Piperazine derivatives useful as CCR5 antagonists | MERCK SHARP & DOHME CORP. | 2004-04-08 | — | — | US | disclosed |
| US-6689765-B2 | VIRICIDES; ANTIINFLAMMATORY AGENTS | SCHERING CORPORATION | 2004-02-10 | — | — | US | disclosed |
| US-20030069252-A1 | Piperazine derivatives useful as CCR5 antagonists | MERCK SHARP & DOHME CORP. | 2003-04-10 | — | — | US | disclosed |
| US-6391865-B1 | AIDS THERAPY; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; SKIN DISORDERS | SCHERING CORPORATION | 2002-05-21 | — | — | US | disclosed |
| EP-1175401-A1 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066558-A1 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR2 | CYP3A4 792/4885MAPT 3008/4885ACHE 3742/4885 |
| US-20030069252-A1 | Piperazine derivatives useful as CCR5 antagonists | CCR5, CCR2, CXCR3 | CYP3A4 914/4885MAPT 3316/4885ACHE 4277/4885 |
| US-20040067961-A1 | Piperazine derivatives useful as CCR5 antagonists | CCR5, CCR2, CXCR3 | CYP3A4 914/4885MAPT 3316/4885ACHE 4277/4885 |
| US-20060105964-A1 | Piperazine derivatives useful as CCR5 antagonists | CCR5, CCR2, CXCR3 | CYP3A4 797/4885MAPT 3024/4885ACHE 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.